Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical Jun 30, 2026 7:32pm EDT
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation Jun 15, 2026 7:30am EDT